Acquisition Momentum SAMDI Tech was acquired by Charles River in January 2023, presenting an opportunity to engage with a larger, integrated client ecosystem and cross-sell HTS label-free technologies within an established network.

HTS Leadership Positioned as a premier provider of label-free high-throughput screening solutions, SAMDI Tech can be pitched for expanded drug discovery collaborations, leveraging its rapid, quantitative SAMDI platform to accelerate client programs.

Small yet nimble With a lean team and revenues in the lower mid-range, there is potential to offer scalable service packages, pilot programs, and cost-effective testing options to attract biotech firms seeking efficient validation studies.

Pipeline Expansion Strategic partnerships with Enamine and continued library expansion suggest opportunities to propose integrated discovery campaigns combining SAMDI’s screening with library outsourcing for end-to-end solutions.

Growth Enablement Target mid-market biotechs and CROs aligned with Charles River’s capabilities for co-marketing, channel partnerships, and bundled offerings to broaden reach in early-stage to translational research stages.